HARROW, INC. (HROW)
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Sector: Pharmaceutical Preparations
HARROW, INC.
Trials need funding. See this company's dilution risk and cash position.
- Phase 4Completed
The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine
Chloroprocaine ophthalmic gel 3%
Antiseptic, Anesthesia, Local
NCT05934253Enrollment100StartJul 2023Primary CompletionJan 2024CompletionFeb 2024 - Phase 4Enrolling by invitation
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD) +2
NCT07456826Enrollment236StartMar 2026Primary CompletionAug 2026est.CompletionAug 2026est. - Phase 4Completed
Tolerability Comparison of Flarex to Lotemax SM
Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%
Ocular Inflammation, Keratoconjunctivitis +5
NCT07588074Enrollment40StartMay 2021Primary CompletionJun 2021CompletionJun 2021 - Phase 3Completed
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
Topical Ketoprofen 10% Cream, Topical Placebo Cream
Sprain, Strain +1
NCT00765700Enrollment364StartSep 2008Primary CompletionAug 2009CompletionSep 2009 - Phase 3Withdrawn
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
Ketoprofen 10% cream, Placebo
Sprain
NCT01223053Enrollment0Start-Primary Completion-Completion- - Phase 3Withdrawn
Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee
Ketoprofen 10% Cream, Placebo
Acute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee
NCT01890902Enrollment0StartAug 2013Primary CompletionJun 2014est.Completion- - Phase 3Enrolling by invitation
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
TRIESENCE (triamcinolone acetonide injectable suspension)
Postoperative Ocular Inflammation, Postoperative Ocular Pain
NCT07832552Enrollment250StartMay 2026Primary CompletionDec 2026est.CompletionMar 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 4 | Completed | Chloroprocaine ophthalmic gel 3% | NCT05934253 |
| Phase 4 | Enrolling by invitation | Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5% | NCT07456826 |
| Phase 4 | Completed | Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38% | NCT07588074 |
| Phase 3 | Completed | Topical Ketoprofen 10% Cream, Topical Placebo Cream | NCT00765700 |
| Phase 3 | Withdrawn | Ketoprofen 10% cream, Placebo | NCT01223053 |
| Phase 3 | Withdrawn | Ketoprofen 10% Cream, Placebo | NCT01890902 |
| Phase 3 | Enrolling by invitation | TRIESENCE (triamcinolone acetonide injectable suspension) | NCT07832552 |